Shanghai Fosun Pharmaceutical (Group) Stock | Analysis for March 2026, Price & Rating

Shanghai Fosun Pharm...

SHSE:600196

¥ 26,13

+ ¥0,84 (3,32%)

26,13 ¥

+¥0,84 (3,32%)

End-of-day quote: 03/27/2026

Shanghai Fosun Pharmaceutical (Group) Stock Value

The analyst rating for SHSE:600196 is currently Outperform.

Outperform

Shanghai Fosun Pharmaceutical (Group) Company Info

EPS Growth 5Y

-3,65%

Market Cap

¥64,30 B

Long-Term Debt

¥11,86 B

Annual earnings

N/A

Dividend

¥0,40

Dividend Yield

1,54%

Founded

1994

Industry

Health Care

Country

China

Website

Shanghai Fosun Pharmaceutical (Group)

ISIN Number

CNE000000X38

Website

http://www.fosunpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

¥34,91

33.6%

Last Update: 03/29/2026

Analysts: 6

Highest Price Target ¥46,00

Average Price Target ¥34,91

Lowest Price Target ¥30,00

In the last five quarters, Shanghai Fosun Pharmaceutical (Group)’s Price Target has risen from ¥19,61 to ¥26,44 - a 34,83% increase. Eight analysts predict that Shanghai Fosun Pharmaceutical (Group)’s share price will increase in the coming year, reaching ¥34,91. This would represent an increase of 33,60%.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Fosun Pharmaceutical (Group) do?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the manufacturing, research, and distribution of a comprehensive range of healthcare products. The company operates across various sectors of the healthcare industry, developing medicines and medical devices while also providing healthcare services and solutions. Business Segments The company is organized into five reportable operating segments, reflecting its diverse offerings within the healthcare domain. Pharmaceutical Manufacturin...

Business Segments

The company is organized into five reportable operating segments, reflecting its diverse offerings within the healthcare domain.

Pharmaceutical Manufacturing Segment: This segment focuses primarily on the production and research of medicines. It employs advanced manufacturing processes and adheres to stringent quality control standards to ensure the efficacy and safety of pharmaceutical products. The segment also invests heavily in research and development (R&D) to foster innovative therapies.

Medical Devices and Medical Diagnosis Segment: In this segment, the company engages in the development and sale of medical devices along with diagnostic products. It utilizes technology to enhance the precision and effectiveness of medical devices that play a crucial role in healthcare delivery.

Healthcare Service Segment: This segment encompasses a range of healthcare services, including hospital management, which allows the company to provide integrated healthcare solutions. With a strong focus on patient-centered care, the company aims to improve healthcare access and service quality.

Pharmaceutical Distribution and Retail Segment: The company manages the wholesale and retail distribution of medicines, ensuring that its products reach healthcare providers and consumers efficiently. This segment also emphasizes the importance of supply chain management for a seamless delivery network.

Other Business Operations Segment: This segment includes a variety of other business ventures that do not fall under the categories. It represents the company's commitment to exploring diverse opportunities within the healthcare sector.

Business Strategy

The company's overarching strategy encompasses a commitment to innovation, digital transformation, and operational excellence. Emphasizing a proactive approach to R&D, the company aims to build an innovative ecosystem through collaboration with top scientific talent and institutions worldwide. This strategy facilitates the development of unique pharmaceutical solutions and reinforces the company's market position.

Furthermore, the company places a strong emphasis on digital transformation, utilizing technology to enhance management practices and operational efficiencies across its divisions. By integrating data analytics and digital solutions into decision-making processes, the company strives to optimize its performance and responsiveness to market demands.

The strategy also includes international expansion, with a focus on cultivating relationships with global partners and establishing a presence in key international markets. By navigating regulatory landscapes and aligning its product offerings to meet the needs of diverse populations, the company aims to increase its global market share and its brand recognition internationally.

Products and Services

The company's extensive portfolio includes a wide array of products and services tailored to address various healthcare needs.

Pharmaceutical Products: The primary offerings include prescription medications targeting various therapeutic areas such as oncology, cardiovascular diseases, and infectious diseases. The company continuously invests in R&D to foster the development of new drug formulations and improve existing therapies.

Medical Devices: The company produces advanced medical devices that cater to diagnostic and therapeutic applications. These devices are developed to enhance patient outcomes and streamline health service delivery through innovation.

Healthcare Services: The company provides comprehensive healthcare services, including hospital management and patient care. Enhanced service delivery models are implemented to improve patient experiences, while the focus remains on delivering care in a timely manner.

Pharmaceutical Distribution: The company operates a robust distribution network, ensuring the availability of its products in pharmacies, hospitals, and clinics. This distribution strategy emphasizes the importance of accessibility in healthcare.

Geographical Markets Served

The company operates in various geographical markets, with a significant presence in the People’s Republic of China and a growing footprint internationally. Through strategic partnerships and collaborations, the company has expanded its reach into several global markets, including North America, Europe, and Asia. The company adapts its strategies and offerings to meet the unique demands of each market, thereby enhancing its competitiveness and reliability as a partner in healthcare.

Customers

The company serves a diverse customer base, which includes hospitals, healthcare providers, and patients. Its customer categories span across various healthcare segments, catering to both institutional and retail customers within its pharmaceutical distribution network.

Sales and Marketing

The company employs a multi-channel sales and marketing approach to effectively reach its diverse customer base. Engaging in direct sales through its own sales teams, as well as indirect sales through partnerships with distributors, the company maximizes its market reach. The marketing strategies focus on educating healthcare professionals and consumers about product benefits and healthcare solutions, while utilizing both traditional and digital marketing channels to enhance brand visibility and engagement.

History

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994.

Shanghai Fosun Pharmaceutical (Group) Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 65% **Healthcare Services:** 20% **Medical Devices and Diagnostics:** 15% **TOP 3 Markets:** **China:** 50% **USA:** 20% **Europe:** 15% Shanghai Fosun Pharmaceutical generates the majority of its revenue from the sale of pharmaceutical products, reflecti...

At which locations are the company’s products manufactured?

**Production Sites:** Multiple sites in China, Portugal, India, and the USA (as of 2023) Shanghai Fosun Pharmaceutical (Group) Co., Ltd. operates a variety of production facilities strategically located in different countries. The headquarters and most production sites are located in China, highlig...

What strategy does Shanghai Fosun Pharmaceutical (Group) pursue for future growth?

**Strategic Focus:** - **International Expansion:** Continuing global market penetration - **Innovation Focus:** Investments in research and development - **Digitalization:** Expansion of digital health solutions Shanghai Fosun Pharmaceutical pursues a strategy aimed at international expansion and...

Which raw materials are imported and from which countries?

**Main Imported Raw Materials:** 1. **Pharmaceutical Active Ingredients (APIs)** 2. **Chemicals for Drug Manufacturing** 3. **Biotechnological Materials** **Main Importing Countries:** 1. **India** 2. **Germany** 3. **USA** Shanghai Fosun Pharmaceutical (Group) Co., Ltd. imports a variety of raw m...

How strong is the company’s competitive advantage?

**Market share in China:** 5% (estimated, 2025) **Research and development investments:** 10% of revenue (2024) **International presence:** 30 countries (2025) Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has a significant competitive advantage due to its strong market position in China and...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** Estimated around 40% (2025) **Insider Buys/Sells:** No specific current data available The institutional investor share in Shanghai Fosun Pharmaceutical is estimated to be around 40%. This reflects the interest of institutional investors in the stock, indicating c...

What percentage market share does Shanghai Fosun Pharmaceutical (Group) have?

**Market share of Shanghai Fosun Pharmaceutical:** 3.5% (2025, estimated) **Top competitors and their market shares:** 1. **Sinopharm Group Co., Ltd.:** 8.2% 2. **China Resources Pharmaceutical Group Limited:** 6.9% 3. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 5.4% 4. **CSPC Pharmaceutical Gr...

Is Shanghai Fosun Pharmaceutical (Group) stock currently a good investment?

**Revenue Growth:** 10% (2024) **Profit Growth:** 8% (2024) **Research & Development (R&D) Expenses:** 12% of Revenue (2024) Shanghai Fosun Pharmaceutical recorded a revenue growth of 10% and a profit growth of 8% in 2024. These growth rates indicate a solid business development supported b...

Does Shanghai Fosun Pharmaceutical (Group) pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2024) **Dividend History:** Continuous payout over the last five years Shanghai Fosun Pharmaceutical has been paying dividends in recent years, demonstrating a certain reliability in its dividend policy. The dividend yield of 2.5% in 2024 indicates a moderate payout that i...

New support ticket

Explore

Shanghai Fosun Pharmaceutical (Group) Stock Value

Shanghai Fosun Pharmaceutical (Group) Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Fosun Pharmaceutical (Group) do?

Shanghai Fosun Pharmaceutical (Group) Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Shanghai Fosun Pharmaceutical (Group) Stock Value

Shanghai Fosun Pharmaceutical (Group) Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Shanghai Fosun Pharmaceutical (Group) do?

Shanghai Fosun Pharmaceutical (Group) Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.